Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jan;20(1):10-12.
doi: 10.1016/S1474-4422(20)30448-8.

Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19

Eng-King Tan  1
Affiliations
Editorial

Movement disorders in 2020: clinical trials, genetic discoveries, and COVID-19

Eng-King Tan. Lancet Neurol. 2021 Jan.
No abstract available

PubMed Disclaimer

References

    1. Tan EK, Albanese A, Chaudhuri K. Adapting to post-COVID19 research in Parkinson's disease: lessons from a multinational experience. Parkinsonism Relat Disord. 2020 doi: 10.1016/j.parkreldis.2020.10.009. published Oct 7. - DOI - PMC - PubMed
    1. Cohen ME, Eichel R, Steiner-Birmanns B. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19:804–805. - PMC - PubMed
    1. Volc D, Poewe W, Kutzelnigg A. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591–600. - PubMed
    1. Mullin S, Smith L, Lee K. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77:427–434. - PMC - PubMed
    1. Olanow CW, Factor SA, Espay AJ. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19:135–144. - PubMed

Publication types

LinkOut - more resources